Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 6451–6500 of 18417
On January 30, 2024, Samuel J. Reich, age 49, the Executive Chairman of the Board of Directors (the “Board”) of SAB Biotherapeutics, Inc. (the “Company”), was appointed Chief Executive Officer of the Company, effective immediately.
On January 29, 2024, Ching W. Jaw, Senior Vice President & Chief Financial Officer, informed Cytokinetics, Incorporated (the "Company") that he would be resigning his office and employment with the Company effective February 23, 2024.
On January 30, 2024, the Board appointed Cherine Pottinger-Harris as the Company's Principal Accounting Officer and interim Chief Financial Officer.
On January 22, 2024, Natalia Vakhitova notified the Board of Directors of Evome Medical Technologies Inc. (the "Company") of her intention to resign as the Company's Principal Accounting Officer and Chief Financial Officer effective on January 22, 2024.
The Company terminated the employment of Mark Doerr, the Company’s President and Chief Executive Officer, and Ramona Seabaugh, the Company’s Chief Financial Officer, Treasurer and Secretary, effective on February 2, 2024
The Company terminated the employment of Mark Doerr, the Company’s President and Chief Executive Officer, and Ramona Seabaugh, the Company’s Chief Financial Officer, Treasurer and Secretary, effective on February 2, 2024
On January 31, 2024, Joseph Marnikovic notified the board of directors (the “Board”) of American Strategic Investment Co. (the “Company”) that he intends to retire and therefore resign from his position as Chief Financial Officer and Treasurer of the Company
On February 2, 2024, the Board appointed Mr. Michael LeSanto, the Company’s Chief Accounting Officer, as the Chief Financial Officer (Principal Accounting Officer and Principal Financial Officer) and Treasurer of the Company
On January 29, 2024, Greenbrook TMS Inc. (the “ Company ”) announced that the Company’s board of directors appointed Mr. Peter Willett, age 34, as the Company’s full-time Chief Financial Officer, effective immediately.
On December 28, 2023, Anthony Rimac, the Chief Financial Officer of Sagimet Biosciences Inc. (the “ Company ”) provided notice of his intent to resign effective January 31, 2024.
On January 31, 2024, the board of directors (the “ Board ”) of the Company appointed Joseph Oriti as Interim Principal Financial Officer and Interim Principal Accounting Officer, effective as of February 1, 2024 (the “ Effective Date ”).
the Company announced the appointment of Eric J. Guerin as the Company’s Chief Financial Officer effective January 15, 2024.
On January 29, 2024, RGC Resources, Inc. ("Resources" or the "Company") appointed Timothy J. Mulvaney, the current Interim Chief Financial Officer and Treasurer, as Vice President, Treasurer and Chief Financial Officer of Resources, effective February 1, 2024.
On January 31, 2024, the Company entered into a Separation Agreement with Mr. Floroiu (the “Separation Agreement”).
Drew D. Hall was elected to the Board of Directors as the sole director of the Company.
the Board appointed Victoria Eatwell as the chief financial officer of the Company, effective as of the date of the Closing.
the Board appointed William D. Baird, III as the president and chief executive officer of the Company, effective as of the date of the Closing.
Phillip Sawarynski, who currently serves as the Company’s Vice President of Corporate Development, Treasurer, and Managing Director and Co-Lead at Trimble Ventures, will become its new Chief Financial Officer effective at the end of May 2024.
On February 1, 2024, Dave Powers announced his intention to retire from his position as Chief Executive Officer and President of Deckers Outdoor Corporation (the “Company”), effective August 1, 2024
On February 1, 2024, the Company announced that Stefano Caroti will be appointed as President and Chief Executive Officer, effective August 1, 2024.
Effective as of February 1, 2024, the Restructuring Committee of the Boards of Directors of the Debtors (which has been vested with the full power and authority of the Boards of Directors of the Debtors with respect to certain activities related to the Debtors’ Chapter 11 Cases) approved that Mr. Pugh, in his capacity as the Debtors’ Chief Transformation Officer, shall assume all of the responsibilities, and the authority to act on behalf of the Debtors, of the Debtors’ acting Chief Financial Officer until a permanent Chief Financial Officer is appointed
David S. Black resigned as Chief Financial Officer of the Company.
On January 29, 2024, the Company entered into an employment agreement (the “ Employment Agreement ”) with Justin C. Jacobs, age 49, pursuant to which Mr. Jacobs was appointed Chief Executive Officer of the Company, effective February 12, 2024
Stephen C. Taylor, the Company’s Interim Chief Executive Officer, will retire although he will provide certain transition services
On January 31, 2024, the Board of Directors (the “Board”) of Immunome, Inc. (the “Company”) promoted Max Rosett, the Company’s Senior Vice President, Operations and Interim Chief Financial Officer to Executive Vice President, Operations and Interim Chief Financial Officer (the “Promotion”).
On January 30, 2024, Trevena, Inc. (the “Company”) promoted Barry Shin to the position of Executive Vice President, Chief Operating Officer & Chief Financial Officer, effective as of February 1, 2024.
appointed Andrew Cohen as Chief Executive Officer of the Company.
On February 1, 2024, the Board of Directors (the “Board”) of DXC Technology Company (the “Company” or “DXC”) appointed Raul J. Fernandez as President and Chief Executive Officer of the Company, effective February 1, 2024.
On January 31, 2024, the board of directors (the “Board”) of Enzo Biochem, Inc. (the “Company”) appointed Kara Cannon to serve as the Chief Executive Officer of the Company and Patricia Eckert, CPA, to serve as the Chief Financial Officer of the Company, in each case, until her successor is duly elected and qualified.
On January 31, 2024, the board of directors (the “Board”) of Enzo Biochem, Inc. (the “Company”) appointed Kara Cannon to serve as the Chief Executive Officer of the Company and Patricia Eckert, CPA, to serve as the Chief Financial Officer of the Company, in each case, until her successor is duly elected and qualified.
the Board appointed Michael Frenz to replace Michael J. Logozzo as the Company’s Chief Financial Officer
On January 26, 2024, Michael White was appointed as Senior Vice President, Chief Accounting Officer of Usio, Inc.
the Company’s Board of Directors (the “Board”) reappointed Mr. Vitale as the Company’s principal executive officer effective January 30, 2024.
Effective upon the commencement of Mr. Doherty's employment, Daniel O'Connell's position would be updated to Chief Executive Officer.
Joseph E. Hart, the Company’s Chief Executive Officer and President; and Michael Ramke, the Company’s Interim Chief Financial Officer, resigned as executive officers of the Company.
Joseph E. Hart, the Company’s Chief Executive Officer and President; and Michael Ramke, the Company’s Interim Chief Financial Officer, resigned as executive officers of the Company.
appointed James M. Jenkins as Acting President and Chief Executive Officer in addition to his role as Executive Chairman, effective February 1, 2024.
Spencer Mash will resign from his position as Chief Financial Officer, Treasurer and Secretary
announced the appointment of Christopher Smith, CFA to the position of Chief Financial Officer, effective February 1, 2024.
appointed Andrew J. ("A.J.") Eaker as the Company's Executive Vice President, Chief Financial Officer (principal financial officer and principal accounting officer), and Treasurer, effective immediately.
Mr. Weihong Liu was appointed as the Chief Executive Officer of the Company, effective January 31, 2024.
On January 31, 2024, CVRx, Inc. (the “Company”) announced that its Board of Directors (the “Board”) appointed Kevin Hykes as President and Chief Executive Officer (“CEO”), effective February 12, 2024.
Mr. Yared will retire from the Board at the time of his retirement as CEO and will consult with the Company to ensure a seamless transition.
the current Chief Financial Officer, Robert E. Landry, who is retiring.
appointed Christopher Fenimore, currently the Company’s Senior Vice President, Controller, as Senior Vice President, Finance and Chief Financial Officer
The Company appointed Mark Mauldin, the Company’s Chief Accounting Officer, to serve as the Company’s interim Chief Financial Officer beginning on February 2, 2024.
Warwick Corden-Lloyd as Chief Financial Officer
Dr. Neil Maresky as Chief Executive Officer
Carl Eschenbach, Workday’s Co-Chief Executive Officer, will serve as Workday’s sole Chief Executive Officer effective the Transition Date.
On January 26, 2024, the Board appointed Mr. Henrichs to serve as the CFO (the “CFO Appointment”). Mr. Henrichs’s employment will begin on February 5, 2024
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.